645 related articles for article (PubMed ID: 27536086)
1. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
Stockley RA; Edgar RG; Pillai A; Turner AM
Int J Chron Obstruct Pulmon Dis; 2016; 11():1745-56. PubMed ID: 27536086
[TBL] [Abstract][Full Text] [Related]
2. Decline in FEV
Hiller AM; Piitulainen E; Jehpsson L; Tanash H
Int J Chron Obstruct Pulmon Dis; 2019; 14():1075-1083. PubMed ID: 31213789
[No Abstract] [Full Text] [Related]
3. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV
Fähndrich S; Bernhard N; Lepper PM; Vogelmeier C; Seibert M; Wagenpfeil S; Bals R
Respir Med; 2017 Aug; 129():8-15. PubMed ID: 28732839
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9 predicts pulmonary status declines in α1-antitrypsin deficiency.
Omachi TA; Eisner MD; Rames A; Markovtsova L; Blanc PD
Respir Res; 2011 Mar; 12(1):35. PubMed ID: 21429222
[TBL] [Abstract][Full Text] [Related]
5. Long-term evolution of lung function in individuals with alpha-1 antitrypsin deficiency from the Spanish registry (REDAAT).
Esquinas C; Serreri S; Barrecheguren M; Rodriguez E; Nuñez A; Casas-Maldonado F; Blanco I; Pirina P; Lara B; Miravitlles M
Int J Chron Obstruct Pulmon Dis; 2018; 13():1001-1007. PubMed ID: 29615836
[TBL] [Abstract][Full Text] [Related]
6. Maximal mid-expiratory flow detects early lung disease in α
Stockley JA; Ismail AM; Hughes SM; Edgar R; Stockley RA; Sapey E
Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28356373
[TBL] [Abstract][Full Text] [Related]
7. Health status and lung function in the Swedish alpha 1-antitrypsin deficient cohort, identified by neonatal screening, at the age of 37-40 years.
Piitulainen E; Mostafavi B; Tanash HA
Int J Chron Obstruct Pulmon Dis; 2017; 12():495-500. PubMed ID: 28203073
[TBL] [Abstract][Full Text] [Related]
8. The impact of smoke exposure on the clinical phenotype of alpha-1 antitrypsin deficiency in Ireland: exploiting a national registry to understand a rare disease.
O'Brien ME; Pennycooke K; Carroll TP; Shum J; Fee LT; O'Connor C; Logan PM; Reeves EP; McElvaney NG
COPD; 2015 May; 12 Suppl 1():2-9. PubMed ID: 25938284
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lung disease in alpha-1 antitrypsin deficiency: a systematic review.
Edgar RG; Patel M; Bayliss S; Crossley D; Sapey E; Turner AM
Int J Chron Obstruct Pulmon Dis; 2017; 12():1295-1308. PubMed ID: 28496314
[TBL] [Abstract][Full Text] [Related]
10. Rate of progression of lung function impairment in alpha1-antitrypsin deficiency.
Dawkins PA; Dawkins CL; Wood AM; Nightingale PG; Stockley JA; Stockley RA
Eur Respir J; 2009 Jun; 33(6):1338-44. PubMed ID: 19164359
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: The Association Between Diagnostic Delay and Worsened Clinical Status.
Tejwani V; Nowacki AS; Fye E; Sanders C; Stoller JK
Respir Care; 2019 Aug; 64(8):915-922. PubMed ID: 30914495
[TBL] [Abstract][Full Text] [Related]
12. Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.
Vijayasaratha K; Stockley RA
Int J Chron Obstruct Pulmon Dis; 2012; 7():789-96. PubMed ID: 23226015
[TBL] [Abstract][Full Text] [Related]
13. A review of alpha-1 antitrypsin deficiency.
Ranes J; Stoller JK
Semin Respir Crit Care Med; 2005 Apr; 26(2):154-66. PubMed ID: 16088434
[TBL] [Abstract][Full Text] [Related]
14. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
[TBL] [Abstract][Full Text] [Related]
15. Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis.
Lange P; Çolak Y; Ingebrigtsen TS; Vestbo J; Marott JL
Lancet Respir Med; 2016 Jun; 4(6):454-62. PubMed ID: 27061878
[TBL] [Abstract][Full Text] [Related]
16. The effect of comorbidities on COPD assessment: a pilot study.
Weinreich UM; Thomsen LP; Bielaska B; Jensen VH; Vuust M; Rees SE
Int J Chron Obstruct Pulmon Dis; 2015; 10():429-38. PubMed ID: 25750525
[TBL] [Abstract][Full Text] [Related]
17. Radiologic and clinical features of COPD patients with discordant pulmonary physiology: lessons from alpha1-antitrypsin deficiency.
Holme J; Stockley RA
Chest; 2007 Sep; 132(3):909-15. PubMed ID: 17573491
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for FEV
Chen S; Wang C; Li B; Shi G; Li H; Zhang J; Gu Y; Zhou J; Song Y; Bai C
Int J Chron Obstruct Pulmon Dis; 2017; 12():435-442. PubMed ID: 28184155
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values.
Pérez-Rubio G; Jiménez-Valverde LO; Ramírez-Venegas A; Camarena Á; Sansores RH; Flores-Trujillo F; Reséndiz-Hernández JM; Falfán-Valencia R
Arch Bronconeumol; 2015 Feb; 51(2):80-85. PubMed ID: 25454901
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Profile of Subjects Included in the Swedish National Register on Individuals with Severe Alpha 1-Antitrypsin deficiency.
Piitulainen E; Tanash HA
COPD; 2015 May; 12 Suppl 1():36-41. PubMed ID: 25938290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
